Spots Global Cancer Trial Database for Safety and Potential Efficacy of MS-20 In Combination With Pembrolizumab for the Treatment of NSCLC

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Safety and Potential Efficacy of MS-20 In Combination With Pembrolizumab for the Treatment of NSCLC

Official Title: A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 In Combination With Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer

Study ID: NCT04909034

Conditions

NSCLC Stage IV

Interventions

MS-20

Placebo

Study Description

Brief Summary: MS-20 was approved as the first oral cancer adjuvant new drug indicated for ameliorating fatigue and appetite loss associated with cancer chemotherapy via reshaping human gut ecosystem and restoring immunity. MS-20 has also been shown to be anti-PD-1 booster by activating tumor-infiltrating lymphocytes (TILs) in mice cancer models, particularly promoting migration of TILs into tumors and increasing the amount of TILs inside tumors. Therefore, this study is designed to explore the safety and relationship between gut microbiome and potential clinical outcomes in NSCLC patients under combination therapy with pembrolizumab and MS-20.

Detailed Description: